



NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research

- Peer-reviewed paper on the encouraging preclinical results of an *in vivo* efficacy study of Nyrada's cholesterol-lowering drug published in the Journal of Lipid Research
- Study is the first to show combination treatment of a small-molecule PCSK9 inhibitor and a statin is highly effective in lowering LDL ("bad") cholesterol
- PCSK9 has been clinically validated as a therapeutic target for the treatment of hypercholesterolemia and atherosclerosis, both leading contributors to cardiovascular disease
- Nyrada is developing an oral PCSK9 inhibitor drug as a convenient and cost competitive alternative to injectable PCSK9 inhibitors, to be taken with or without a statin
- Despite 27 million US adults taking statins, an estimated 70% are unable to reach a safe target cholesterol level
- Cholesterol-Lowering Program Phase I expected to commence in H1 CY2023

Sydney, 10 October 2022: Nyrada Inc (ASX: NYR) ("Nyrada" or "the Company") a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announced the publication of a peer-reviewed scientific paper in the preeminent Journal of Lipid Research, authored by Nyrada's Chief Scientific Officer, Dr. Benny Evison and Director of Preclinical Development, Dr. Alexandra Suchowerska.

The paper entitled, '*A novel, orally bioavailable, small-molecule inhibitor of PCSK9 with significant cholesterol-lowering properties in vivo*' outlines the results of a [previously announced](#) efficacy study in hyperlipidemic APOE*3-Leiden.CETP mice, in which NYX-PCSK9i was shown to reduce total cholesterol by 57%.¹ No adverse effects were identified and NYX-PCSK9i was well-tolerated.

For many individuals at risk of cardiovascular disease, statin monotherapy is often insufficient to achieve their LDL-cholesterol targets. The study confirmed the suitability of NYX-PCSK9i as a potential oral treatment that could be combined with a statin in a single pill, for the large cohort of patients that cannot reach their targeted LDL-cholesterol levels taking a statin alone.

Nyrada Chief Scientific Officer, Dr. Benny Evison said, "It is pleasing that the significant cholesterol-lowering result achieved in this study has been recognised by the Journal of Lipid Research. The paper was reviewed and approved by independent experts in the field, so their recommendation to publish indicates our science is sufficiently rigorous and novel to warrant inclusion in such a well-respected journal."

The Company intends to present the paper at upcoming conferences both in Australia and overseas.

¹ Journal of Lipid Research: [https://www.jlr.org/article/S0022-2275\(22\)00126-2/fulltext](https://www.jlr.org/article/S0022-2275(22)00126-2/fulltext)



About the APOE*3-Leiden.CETP mouse model

Nyrada selected a specialised mouse model for the study called the APOE*3-Leiden.CETP mouse model, which has been specifically generated to possess human-like characteristics concerning cholesterol metabolism and cardiovascular health. The model expresses three human genes to specifically model the human hyperlipidaemia condition and is very well regarded in the cardiovascular field, having been used for over 170 drug intervention studies by the pharmaceutical industry over the last 15 years.

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize, Investor Relations Manager
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.